3-Dimensional Pharmaceuticals Inc., of Exton, Pa., named John Gill chief financial officer.
Aclara BioSciences Inc., of Mountain View, Calif., chose Dennis Harris as its senior vice president of research and development.
AtheroGenics Inc., of Atlanta, appointed Martin Wasserman vice president, discovery research and chief scientific officer.
Atrix Laboratories Inc., of Fort Collins, Colo., added Mark Sweeney as director of quality assurance and Chris French as director of technical affairs.
Avant Immunotherapeutics Inc., of Needham, Mass., appointed Michael Henry vice president, business development.
Battelle Pulmonary Therapeutics Inc., of Columbus, Ohio, added Bethany Beck as vice president and general counsel; Charles Bramlage as senior vice president and general manager, drug delivery; Suketu Desai as director, pharmaceutical development; and David Westaway as senior vice president and general manager, oncology.
BioCurex Inc., of Rancho Santa Margarita, Calif., named the members of its scientific advisory board: Phil Gold, Garri Abelev, Jose Uriel, Maria Jose Villacampa, Taiki Tamaoki, Elliot Alpert and Michel Sadelain.
Bruker AXS Inc., of Madison, Wis., appointed John Bourke as chief financial officer and treasurer.
Corgentech Inc., of South San Francisco, appointed Todd Lorenz chief medical officer.
DepoMed Inc., of Menlo Park, Calif., elected Julian Stern to its board.
Discovery Laboratories Inc., of Doylestown, Pa., appointed Mark Siegel to its board.
Edwards Lifesciences Corp., of Irvine, Calif., elected Corinne Lyle to its board.
eMedsecurities Inc., of New York, appointed Vanessa Burgess head of investment banking.
EntreMed Inc., of Rockville, Md., appointed Edward Gubish president and chief operating officer and Neil Campbell vice president of corporate development.
EpiGenX Pharmaceuticals Inc., of Santa Barbara, Calif., added Yuan-Tseh Lee to its scientific advisory board.
Exact Sciences Corp., of Maynard, Mass., promoted Anthony Shuber to senior vice president and chief technology officer.
Genentech Inc., of South San Francisco, promoted David Ebersman to senior vice president, product operations.
GPC Biotech AG, of Martinsried, Germany, appointed Marcel Rozencweig senior vice president of drug development.